|
業務類別
|
Diagnostics & Research |
|
業務概覽
|
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection. |
| 公司地址
| 13011 McCallen Pass, Building A Suite 100, Austin, TX, USA, 78753 |
| 電話號碼
| +1 650 980-9190 |
| 傳真號碼
| +1 650 456-2122 |
| 公司網頁
| https://www.natera.com |
| 員工數量
| 6140 |
| Mr. Michael Brophy |
Chief Financial Officer and Principal Accounting Officer |
美元 562.79K |
23/04/2026 |
| Mr. Steven Leonard Chapman |
Director, Chief Executive Officer and Co-President |
美元 853.71K |
23/04/2026 |
| Mr. Daniel Rabinowitz |
Secretary and Chief Legal Officer |
-- |
23/04/2026 |
| Mr. Solomon Moshkevich |
President, Clinical Diagnostics |
美元 504.65K |
23/04/2026 |
| Mr. John Fesko |
Co-President and Chief Business Officer |
美元 504.65K |
23/04/2026 |
|
|
| Mr. Eric N. Rubino |
Director |
01/04/2026 |
| Mr. Herm Rosenman |
Independent Director |
23/04/2026 |
| Ms. Ruth Williams Brinkley |
Independent Director |
23/04/2026 |
| Dr. Thomas J. Lynch, Jr,M.D. |
Independent Director |
05/06/2026 |
| Mr. Roelof Frederik Botha |
Lead Independent Director |
23/04/2026 |
| Dr. Matthew Rabinowitz |
Executive Chairman of the Board |
23/04/2026 |
| Mr. Jonathan Sheena |
Director |
23/04/2026 |
| Dr. Roy D. Baynes, M.D.,PhD |
Independent Director |
23/04/2026 |
| Dr. Gail B. Marcus |
Independent Director |
23/04/2026 |
| Mr. Steven Leonard Chapman |
Director, Chief Executive Officer and Co-President |
23/04/2026 |
| Dr. Rowan E. Chapman, PhD |
Independent Director |
23/04/2026 |
|
|
|
|
